Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 2 (2005), Issue 11 (November)

  1. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis.
    Int J Cancer, 118(1): 62-73. [Abstract] [Full-text]
  2. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
    Int J Cancer, 118(1): 222-9. [Abstract] [Full-text]
  3. Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells.
    Cancer Res, 65(21): 9934-42. [Abstract] [Full-text]
  4. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer.
    Cancer Res, 65(21): 9906-13. [Abstract] [Full-text]
  5. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation.
    Cancer Res, 65(21): 9891-8. [Abstract] [Full-text]
  6. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.
    Cancer Res, 65(21): 9807-16. [Abstract] [Full-text]
  7. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis.
    Cancer Res, 65(21): 9789-98. [Abstract] [Full-text]
  8. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness.
    Cancer Res, 65(21): 9762-70. [Abstract] [Full-text]
  9. Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase.
    Cancer Res, 65(21): 9617-22. [Abstract] [Full-text]
  10. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Cancer Res, 65(21): 9611-6. [Abstract] [Full-text]
  11. Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells.
    Oncogene, 24(48): 7203-12. [Abstract] [Full-text]
  12. Molecular characterisation of the t(1;15)(p22;q22) translocation in the prostate cancer cell line LNCaP.
    Cytogenet Genome Res, 112(1): 45-52. [Abstract] [Full-text]
  13. Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favourable toxicity profile.
    Int J Hyperthermia, 21(7): 649-56. [Abstract] [Full-text]
  14. Life-threatening meningitis resulting from transrectal prostate biopsy.
    Asian J Androl, 7(4): 453-5. [Abstract] [Full-text]
  15. Contragestazol (DL111-IT) inhibits proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo.
    Asian J Androl, 7(4): 389-93. [Abstract] [Full-text]
  16. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
    Asian J Androl, 7(4): 375-80. [Abstract] [Full-text]
  17. Recent neuroanatomical studies on the neurovascular bundle of the prostate and cavernosal nerves: clinical reflections on radical prostatectomy.
    Asian J Androl, 7(4): 339-49. [Abstract] [Full-text]
  18. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
    Urology, 66(5): 1060-5. [Abstract] [Full-text]
  19. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Urology, 66(5): 1054-9. [Abstract] [Full-text]
  20. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy.
    Urology, 66(5): 1048-53. [Abstract] [Full-text]
  21. Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies.
    Urology, 66(5): 1043-7. [Abstract] [Full-text]
  22. Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages.
    Urology, 66(5): 1038-42. [Abstract] [Full-text]
  23. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
    Urology, 66(5): 1029-33. [Abstract] [Full-text]
  24. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer.
    Urology, 66(5): 1024-8. [Abstract] [Full-text]
  25. Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer.
    Urology, 66(5): 1020-3. [Abstract] [Full-text]
  26. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients.
    Urology, 66(5): 1015-9. [Abstract] [Full-text]
  27. Chromogranin A expression in familial versus sporadic prostate cancer.
    Urology, 66(5): 1010-4. [Abstract] [Full-text]
  28. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome.
    Urology, 66(5): 930-4. [Abstract] [Full-text]
  29. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.
    Tumour Biol, 26(6): 324-36. [Abstract] [Full-text]
  30. Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients.
    Int J Cancer, 118(2): 518-20. [Abstract] [Full-text]
  31. Akt-regulated pathways in prostate cancer.
    Oncogene, 24(50): 7465-74. [Abstract] [Full-text]
  32. Development and evaluation of a prostate sexual rehabilitation clinic: a pilot project.
    BJU Int, 96(9): 1360-4. [Abstract] [Full-text]
  33. Perianal and intrarectal anaesthesia for transrectal biopsy of the prostate: a prospective randomized study comparing lidocaine-prilocaine cream and placebo.
    BJU Int, 96(9): 1264-7. [Abstract] [Full-text]
  34. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
    BJU Int, 96(9): 1258-63. [Abstract] [Full-text]
  35. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
    BJU Int, 96(9): 1253-7. [Abstract] [Full-text]
  36. Factors contributing to the racial differences in prostate cancer mortality.
    BJU Int, 96(9): 1247-52. [Abstract] [Full-text]
  37. A tumour stem cell hypothesis for the origins of prostate cancer.
    BJU Int, 96(9): 1219-23. [Abstract] [Full-text]
  38. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse.
    Endocrinology, 146(12): 5188-96. [Abstract] [Full-text]
  39. Evaluation of lipophilins as determinants of tumor cell response to estramustine.
    J Pharmacol Exp Ther, 315(3): 1158-62. [Abstract] [Full-text]
  40. Contact stimulation of prostate cancer cell migration: the role of gap junctional coupling and migration stimulated by heterotypic cell-to-cell contacts in determination of the metastatic phenotype of Dunning rat prostate cancer cells.
    Biol Cell, 97(12): 893-903. [Abstract] [Full-text]
  41. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Int J Radiat Oncol Biol Phys, 63(5): 1463-8. [Abstract] [Full-text]
  42. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
    Int J Radiat Oncol Biol Phys, 63(5): 1455-62. [Abstract] [Full-text]
  43. Effect of post-implant edema on prostate brachytherapy treatment margins.
    Int J Radiat Oncol Biol Phys, 63(5): 1469-73. [Abstract] [Full-text]
  44. A phase III randomized, placebo-controlled, double-blind study of misoprostol rectal suppositories to prevent acute radiation proctitis in patients with prostate cancer.
    Int J Radiat Oncol Biol Phys, 63(5): 1488-93. [Abstract] [Full-text]
  45. Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients.
    Int J Radiat Oncol Biol Phys, 63(5): 1483-7. [Abstract] [Full-text]
  46. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
    Int J Radiat Oncol Biol Phys, 63(5): 1474-82. [Abstract] [Full-text]
  47. An evaluation of general and spinal anesthesia techniques for prostate brachytherapy in a day surgery setting.
    Anesth Analg, 101(6): 1656-8. [Abstract] [Full-text]
  48. Prostate epithelial stem cells.
    Cell Prolif, 38(6): 363-74. [Abstract] [Full-text]
  49. Antibody levels against BK virus and prostate, kidney and bladder cancers in the EPIC-Oxford cohort.
    Br J Cancer, 93(11): 1305-6. [Abstract] [Full-text]
  50. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse.
    Br J Cancer, 93(11): 1285-94. [Abstract] [Full-text]
  51. Prostate cancer: three-dimensional sonoelastography for in vitro detection.
    Radiology, 237(3): 981-5. [Abstract] [Full-text]
  52. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
    Cancer Chemother Pharmacol, 57(1): 46-51. [Abstract] [Full-text]
  53. Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.
    J Surg Oncol, 92(4): 326-30. [Abstract] [Full-text]
  54. E2F1 expression in LNCaP prostate cancer cells deregulates androgen dependent growth, suppresses differentiation, and enhances apoptosis.
    Prostate, 66(1): 70-81. [Abstract] [Full-text]
  55. Effect of increasing ratio of estrogen: androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP.
    Prostate, 66(1): 105-14. [Abstract] [Full-text]
  56. Differential attenuation of oxidative/nitrosative injuries in early prostatic neoplastic lesions in TRAMP mice by dietary antioxidants.
    Prostate, 66(1): 57-69. [Abstract] [Full-text]
  57. Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation.
    Prostate, 66(1): 82-7. [Abstract] [Full-text]
  58. Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer.
    Prostate, 66(1): 97-104. [Abstract] [Full-text]
  59. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue.
    Prostate, 66(1): 13-8. [Abstract] [Full-text]
  60. Changes in gap junctional connexin isoforms during prostate cancer progression.
    Prostate, 66(1): 19-31. [Abstract] [Full-text]
  61. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
    Prostate, 66(1): 32-48. [Abstract] [Full-text]
  62. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma.
    Prostate, 66(1): 49-56. [Abstract] [Full-text]
  63. Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival.
    Biochem Biophys Res Commun, 339(1): 93-8. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

The Prostate Cancer Protection Plan : The Foods, Supplements, and Drugs that Can Combat Prostate Cancer

The Prostate Cancer Protection Plan : The Foods, Supplements, and Drugs that Can Combat Prostate Cancer